Galanin
Cognitive / NeuromodulationAlso known as: GAL
Mechanism
A 30-amino acid neuropeptide that modulates the release of several key neurotransmitters including acetylcholine, serotonin, norepinephrine, and dopamine. It regulates cognition, mood, pain, feeding, and hormone release. Galanin receptor agonists are being studied as potential treatments for Alzheimer's disease and epilepsy because galanin has both neuroprotective and anticonvulsant properties.
Technical detail
30-amino acid neuropeptide (29 aa in humans, C-terminally amidated in most species except humans). Signals through three GPCRs: GalR1 (Gi/o → inhibit cAMP, open GIRK channels), GalR2 (Gq/11 → activate PLC/PKC, also Gi), GalR3 (Gi/o → inhibit cAMP). Widely expressed in CNS and PNS. Cognition: galanin inhibits acetylcholine release in hippocampus (basal forebrain cholinergic neurons co-express galanin). Galanin overexpression in transgenic mice impairs spatial memory. However, galanin is also neuroprotective — upregulated after seizures and injury, protecting neurons from excitotoxicity. Epilepsy: galanin is an endogenous anticonvulsant; GalR1 agonists reduce seizure severity in animal models. Pain: expressed in DRG neurons, modulates nociceptive processing (upregulated after nerve injury). Alzheimer's: galanin-hyperinnervation of surviving cholinergic neurons may be compensatory/neuroprotective (Counts et al., 2003). NAX 5055 (galanin analog) in preclinical development for epilepsy.
Effects
## Detailed Effects — Galanin ### Central Nervous System — Neuromodulation [Tier 2] - Endogenous 29-amino acid (30 in humans) neuropeptide widely distributed in the CNS: hypothalamus, hippocampus, locus coeruleus, amygdala, spinal cord dorsal horn. - Three receptor subtypes: GalR1 (inhibitory, Gi-coupled), GalR2 (excitatory/mixed, Gq and Gi-coupled), GalR3 (inhibitory, Gi-coupled). - **Pain modulation**: Galanin is released in the spinal cord dorsal horn and modulates nociceptive processing. GalR1 activation is analgesic (inhibits pain signaling); GalR2 activation can be pro- or anti-nociceptive depending on context. - **Seizure protection**: Galanin is a potent endogenous anticonvulsant. Released during seizures as a negative feedback mechanism. GalR1 activation in the hippocampus inhibits glutamate release and suppresses seizure propagation. Galanin knockout mice have increased seizure susceptibility and higher seizure-related mortality. - **Mood and anxiety**: Complex role — GalR1/GalR3 activation in the amygdala and locus coeruleus modulates anxiety and depression-like behavior. Both anxiolytic and anxiogenic effects reported depending on receptor subtype and brain region. - **Cognition**: Galanin inhibits acetylcholine release in the hippocampus (GalR1-mediated) — can impair memory formation at high concentrations. However, GalR2 activation promotes hippocampal neurogenesis. - **Alzheimer's disease**: Galanin is hyperexpressed in surviving cholinergic neurons in AD brains — may be neuroprotective (GalR2-mediated) but also contributes to cholinergic deficit. ### Neuroendocrine System [Tier 2] - Stimulates growth hormone release (GalR1 on pituitary somatotrophs). - Inhibits insulin secretion from pancreatic beta cells (GalR1-mediated). - Modulates prolactin, LH, and TSH secretion. - Regulates feeding behavior — orexigenic effect when injected into the paraventricular nucleus, particularly promoting fat intake. ### Pain Systems [Tier 2] - Upregulated in dorsal root ganglia following peripheral nerve injury — part of the endogenous pain modulation response. - GalR1 agonists are being explored as novel analgesic agents for neuropathic pain. - GalR2 agonists may promote nerve regeneration after injury. ### Immune System [Tier 3] - Expressed in immune cells (macrophages, T cells). Modulates inflammatory cytokine release. - May play a role in neuroinflammation — relevant to neurodegenerative disease.
Practitioner Guide
## Practitioner Guide — Galanin ### Clinical Context - Galanin is an ENDOGENOUS neuropeptide — NOT currently available as a therapeutic drug. - No FDA-approved galanin receptor agonists or antagonists exist. - Active pharmaceutical interest in GalR1 agonists (pain, epilepsy) and GalR2 agonists (neurogenesis, neurodegeneration). - Research-grade galanin peptide available for laboratory use only. ### Why This Peptide Matters Clinically 1. **Epilepsy drug target**: GalR1 agonists represent a novel mechanism for seizure control — could benefit patients with drug-resistant epilepsy. 2. **Neuropathic pain**: GalR1 agonists could provide non-opioid analgesia. 3. **Alzheimer's disease**: GalR2 agonists may be neuroprotective and promote neurogenesis — in preclinical development. 4. **Biomarker potential**: Galanin levels may help characterize pain subtypes, seizure susceptibility, or neurodegenerative disease stage. ### Endogenous Galanin Modulation Strategies - **Exercise**: Physical activity modulates galanin expression in the locus coeruleus and hippocampus — contributes to exercise-induced mood and cognitive benefits. - **Sleep**: Galanin neurons in the ventrolateral preoptic area (VLPO) are critical for sleep initiation. Sleep deprivation disrupts galanin signaling. - **Stress management**: Chronic stress alters galanin expression patterns — stress reduction practices may normalize galanin signaling. ### Research Use Only - Galanin (human, 1-30): lyophilized powder, reconstitute in sterile water or DMSO. Store at -20°C. - Galanin receptor-selective analogs: M617 (GalR1 selective), AR-M1896 (GalR2 selective) — research tools. - Half-life in vivo: very short (~5-7 minutes IV). Intranasal delivery being explored for CNS access. ### Storage (Research) - Lyophilized peptide: -20°C. Reconstituted solutions: aliquot and store at -20°C, avoid freeze-thaw cycles. - Peptide is susceptible to oxidation at Met residues.
Research Summary
## Research Summary — Galanin ### Tier 1: Randomized Controlled Trials - No RCTs of exogenous galanin administration in humans. - GalR1 and GalR2 selective agonists are in preclinical/early clinical development. ### Tier 2: Systematic Reviews & Key Studies - **Mazarati et al., multiple publications (2000-2020)**: Extensive characterization of galanin's anticonvulsant role. Galanin knockout mice show lethal seizure phenotype. GalR1 activation in the hippocampus is anticonvulsant. - **Webling et al., EJP 2012**: Comprehensive review of galanin receptor pharmacology and therapeutic potential. - **Counts et al., PNAS 2005**: Galanin hyperinnervation of cholinergic basal forebrain neurons in Alzheimer's disease — may be neuroprotective via GalR2. - **Hobson et al., Ann NY Acad Sci 2008**: Review of galanin in pain and nociception. GalR1 agonists as potential analgesics for neuropathic pain. - Extensive preclinical literature (hundreds of papers) on galanin in seizures, pain, mood, feeding, and neurodegeneration. ### Tier 3: Case Reports & Practitioner Protocols - Galanin gene polymorphisms (e.g., rs948854) have been associated with depression, epilepsy risk, and Alzheimer's disease susceptibility — clinical genetic testing not yet standard. - No established clinical protocols for galanin administration. - Academic interest in galanin gene therapy for drug-resistant epilepsy (viral vector delivery of galanin gene to seizure foci). ### Gaps - No human clinical trials of galanin or galanin receptor agonists/antagonists (as of 2026). - Translation of robust preclinical data to human therapeutics has been slow — peptide instability and CNS delivery are major hurdles. - The dual/opposing roles of GalR1 vs GalR2 in cognition and mood complicate drug design. ### Active Trials - GalR1 agonist programs for epilepsy and neuropathic pain in preclinical development (multiple pharmaceutical companies). - Galanin gene therapy for epilepsy in preclinical models. - GalR2 agonist programs for Alzheimer's disease and neurodegeneration.